The stock of Abbott Laboratories (ABT) has seen a 2.45% increase in the past week, with a 7.28% gain in the past month, and a 1.43% flourish in the past quarter. The volatility ratio for the week is 2.39%, and the volatility levels for the past 30 days are at 2.74% for ABT. The simple moving average for the past 20 days is 3.16% for ABT’s stock, with a 11.73% simple moving average for the past 200 days.
Is It Worth Investing in Abbott Laboratories (NYSE: ABT) Right Now?
Abbott Laboratories (NYSE: ABT) has a higher price-to-earnings ratio of 17.38x compared to its average ratio, The 36-month beta value for ABT is at 0.74. Analysts have varying views on the stock, with 13 analysts rating it as a “buy,” 7 rating it as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for ABT is 1.73B, and currently, shorts hold a 1.26% of that float. The average trading volume for ABT on May 08, 2025 was 7.11M shares.
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT) has seen a rise in its stock price by 0.67 in relation to its previous close of 133.06. However, the company has experienced a 2.45% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-07 that Despite trade policy challenges, Abbott’s global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at 2.58% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.15% of loss for the given period.
Volatility was left at 2.74%, however, over the last 30 days, the volatility rate increased by 2.39%, as shares surge +8.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.38% lower at present.
During the last 5 trading sessions, ABT rose by +2.45%, which changed the moving average for the period of 200-days by +31.28% in comparison to the 20-day moving average, which settled at $129.85. In addition, Abbott Laboratories saw 18.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Blount Sally E., who sale 2,600 shares at the price of $129.66 back on Apr 30 ’25. After this action, Blount Sally E. now owns 34,058 shares of Abbott Laboratories, valued at $337,116 using the latest closing price.
SALLY E BLOUNT, the Director of Abbott Laboratories, proposed sale 2,600 shares at $129.66 during a trade that took place back on Apr 30 ’25, which means that SALLY E BLOUNT is holding shares at $337,116 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.56 for the gross margin
The net margin for Abbott Laboratories stands at 0.32. The total capital return value is set at 0.1. Equity return is now at value 30.66, with 17.45 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.68. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is 15.39.
Currently, EBITDA for the company is 10.83 billion with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 5.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
In conclusion, Abbott Laboratories (ABT) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
